Regorafenib 40 mg (Regorafenib)

Contact us for more information
Wishlist Compare
Brand nameResihanceInternational trade nameStivargaActive substanceRegorafenibStrength40mgCategoryAnti Cancer

Description of Resihance 40mg (Regorafenib 40mg)

Resihance 40mg (Regorafenib 40mg) is an antineoplastic Medicinewhichprohibit with the growth and spread of cancer cells in the body.

Resihance 40mg (Regorafenib 40mg) is needed to treat colorectal cancer and liver cancer. It is also needed to treat a rare type of tumor which can affect the oesophagus, stomach, or intestines.

Resihance 40mg (Regorafenib 40mg) is commonly given after other cancer regimens have been tried without success.

Resihance 40mg (Regorafenib 40mg) is a prescription Medicines which is used under the supervision of medical practioners.

Medical use /Indication of Resihance 40mg (Regorafenib 40mg)

Resihance 40mg (Regorafenib 40mg) is indicated for the treatmentof metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy 
Resihance 40mg (Regorafenib 40mg) is indicated for the treatment of unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib
Resihance 40mg (Regorafenib 40mg) is indicated for the treatment of hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Mechanism of Action Resihance 40mg (Regorafenib 40mg)

Regorafenib belongs to oral tumour deactivation agent which potently stops multiple protein kinases, contain kinases included in tumour angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF, BRAFV600E), metastasis (VEGFR3, PDGFR, FGFR) and tumour immunity (CSF1R). Regorafenib prohibits mutated KIT, a major oncogenic driver in gastrointestinal stromal tumours, and thereby stops tumour cell multiplication. In preclinical studies regorafenib has described potent anticancer activity in a broad spectrum of tumour models containing colorectal, gastrointestinal stromal and hepatocellular tumour models which is likely mediated by its anti-angiogenic and anti-proliferative effects. In addition, regorafenib decreased the levels of tumour analogue macrophages and has shown anti-metastatic effects in vivo. Major human metabolites (M-2 and M-5) displayed similar efficacies, compared to regorafenib in in vitro and in vivo models.

ADME of Resihance 40mg (Regorafenib 40mg)

Absorption of Resihance 40mg (Regorafenib 40mg)

time to peak plasma is 4 hours and concentration is 2.5mcg/mL for single dose; 3.9mcg/mL for steady state and bioavailability is 69-83%

Distribution of Resihance 40mg (Regorafenib 40mg)

regorafenib has protein bounding about 99.5% and M-2 active metabolite is 99.8%; M-5 active metabolite is 99.95%

Metabolism of Resihance 40mg (Regorafenib 40mg)

Regorafenib is metabolized by CYP3A4 and UGT1A9

Elimination of Resihance 40mg (Regorafenib 40mg)

excreted via feces 71%; 19% urine (within 12 days of single dose)
Half-life of
Regorafenib is 28 hr
M-2 active metabolite is 25 hr
M-5 active metabolite is 51hr

Side effects of Resihance 40mg (Regorafenib 40mg)

Common side effects occurring in greater than 30% :

Hand-foot syndrome , Diarrhea, Low platelets, Mouth sores/inflammation, Weight loss, Infection, Anemia, Increased liver enzymes (AST, ALT), Fatigue, High blood pressure, Voice disorder (Dysphonia), Protein in the urine, Low calcium, Low phosphorous, Low white blood cells, Decreased appetite, Increased lipase & amylase, High bilirubin in the blood, Low sodium, Nausea.

Less common side effects occurring in about 10-29% of patients receiving Resihance 40mg (Regorafenib 40mg) :

Pain, Fever, Rash, Low potassium, Decreased blood clotting, Increased bleeding, Headache, Alopecia.

Precautions of Resihance 40mg (Regorafenib 40mg)

Myocardial ischemia and infarction seen in clinical trials; withhold Resihance 40mg (Regorafenib 40mg)  for new or acute cardiac ischemia/infarction and restart only after resolution of acute ischemic events

While treatment with Resihance 40mg (Regorafenib 40mg) , one case report of reversible posterior leukoencephalopathy syndrome (RPLS) reported (1 of 1100 treated patients); interrupt therapy if RPLS occurs

serious Medicine-induced liver injury with fatal outcome appeared in Resihance 40mg (Regorafenib 40mg) -treated patients in clinical trials. Some of the cases, liver dysfunction resulted within the first 2 months of treatment and was characterized by a hepatocellular pattern of injury.

While treatment with Resihance 40mg (Regorafenib 40mg)  will Increases risk for haemorrhage; stop therapy for severe or life-threatening haemorrhage

While treatment with Resihance 40mg (Regorafenib 40mg)  will Increased risk of infections resulted; most common infections contains urinary tract infections, nasopharyngitis, mucocutaneous and systemic fungal infections and pneumonia

While treatment with Resihance 40mg (Regorafenib 40mg)  will Increases risk for HFSR/PPES and rash; a higher incidence of HFSR resulted in Asian patients; discontinue and then decrease or stop regorafenib depending on severity and persistence of dermatologic toxicity

Drug interaction of Resihance 40mg (Regorafenib 40mg)

Resihance 40mg (Regorafenib 40mg) concomitant use with strong CYP3A4 inducers will decrease Regorafenib plasma concentrations and increased plasma concentration of active metabolite M-2; M-5.

Resihance 40mg (Regorafenib 40mg) interaction with strong CYP3A4 inhibitor will increase Regorafenib plasma concentration and reduced plasma concentration of active metabolite M-2; M-5.

Resihance 40mg (Regorafenib 40mg) interaction with BCRP substrate will increased the plasma concentration of the BCRP substrate.

Pregnancy of Resihance 40mg (Regorafenib 40mg)

There are no data available on use in pregnant women. Advise female about the possible hazard to a fetus.

Lactation of Resihance 40mg (Regorafenib 40mg)

Excretion into human milk is unknown

Avoid breast feeding during the treatment with Resihance 40mg (Regorafenib 40mg)

Dosage of Resihance 40mg (Regorafenib 40mg)

Colorectal cancer :

The usual dose is 160mg (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.

Gastrointestinal stromal tumor :

The usual dose is 160mg (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.

Hepatocellular carcinoma :

The usual dose is 160mg (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.

Follow the treatment of this conditions until disease progression or undesirable toxicity

Storage of Resihance 40mg (Regorafenib 40mg)

Store the Resihance 40mg (Regorafenib 40mg) at 25℃ (77℃)

Keep the Medicine in its original container bottle

Keep the bottle tightly closed after one time used

Missed dose of Resihance 40mg (Regorafenib 40mg)

If dose is missed, patients must consult with medical practitioner and follow the instructions given by them. Thereby missed dose should be avoid and follow the regular dosing schedule

Brand name:
International trade name:
Active substance:
Anti Cancer
28 Tablets
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India